Equip EHV Injection (10 Dose)
Inactivated EHV1, strain 438/77: not less than 107.3 TCID50, inactivated EHV4, strain 405/76: not less than 107.3 TCID50 and 6 mg Carbopol 934P as adjuvant.
For active immunisation of horses to reduce clinical signs due to infection with Equine Herpesvirus 1 and 4 and to reduce abortion caused by EHV-1 infection.
Dosage and administration
One dose per horse to be administered by deep intramuscular injection.
A single dose should be administered from 5 months of age followed by a second injection after an interval of 4-6 weeks.
In the event of increased infection risk, for example when a foal has consumed insufficient colostrum or there is a risk of early exposure to field infections with EHV-1 or EHV-4, earlier vaccination may be given. In these circumstances the foal should receive a single dose from 3 months of age followed by the above mentioned full primary vaccination course.
Following completion of the primary course, a single dose should be administered every 6 months.
Use in pregnant mares:
To reduce abortion due to EHV-1 infection, pregnant mares should be vaccinated during the 5th, 7th and 9th month of pregnancy with a single 1.5 ml dose on each occasion.
Contra-indications, warnings, etc
FOR ANIMAL TREATMENT ONLY
Do not vaccinate unhealthy horses.
Can be used during pregnancy.
No information is available on the compatibility of this vaccine with any other. Therefore the safety and efficacy of this product when used with any other (either when used on the same day or at different times) has not been demonstrated.
Do not mix with any other medicinal product.
The vaccine may not be effective in animals incubating the disease at the time of vaccination.
In the event of an allergic or anaphylactic reaction, immediate treatment should be given with a soluble glucocorticoid intravenously (e.g. dexamethasone sodium phosphate), adrenaline intramuscularly or anti-histamine intramuscularly.
Animals that have received immunosuppressive drugs (e.g. glucocorticoids) should not be vaccinated until an interval of at least 4 weeks has elapsed.
Syringes and needles should not have been sterilised chemically or be above ambient temperature. Do not use chemicals to disinfect or sterilise the skin.
Shake well before use.
Aseptic precautions should be observed.
In cases of local reaction, swellings usually measure not more than 5 cm diameter and disappear within 10 days post vaccination.
Keep out of the reach and sight of children.
The vaccine has to be stored and transported in its original unopened undamaged packing in the dark at +2°C - +8°C. Exposure to heat and/or direct sunlight has to be avoided. Do not freeze.
2, 10 and 50 dose packs.
Not all pack sizes may be marketed.